Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial

Autor: Adrian Murray Brunt, Joanne S Haviland, Duncan A Wheatley, Mark A Sydenham, Abdulla Alhasso, David J Bloomfield, Charlie Chan, Mark Churn, Susan Cleator, Charlotte E Coles, Andrew Goodman, Adrian Harnett, Penelope Hopwood, Anna M Kirby, Cliona C Kirwan, Carolyn Morris, Zohal Nabi, Elinor Sawyer, Navita Somaiah, Liba Stones, Isabel Syndikus, Judith M Bliss, John R Yarnold, Anne Armstrong, Judith Bliss, David Bloomfield, Jo Bowen, Murray Brunt, Hannah Chantler, Charlotte Coles, Ellen Donovan, Andy Goodman, Susan Griffin, Jo Haviland, Penny Hopwood, Anna Kirby, Julie Kirk, Cliona Kirwan, Marjory MacLennan, Mark Sculphur, Judith Sinclair, Mark Sydenham, Jean Tremlett, Karen Venables, Duncan Wheatley, John Yarnold

Publikováno v: Lancet (London, England)
FAST-Forward Trial Management Group 2020, ' Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward) : 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial ', Lancet (London, England), vol. 395, no. 10237, pp. 1613-1626 . https://doi.org/10.1016/S0140-6736(20)30932-6

BACKGROUND: We aimed to identify a five-fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 1 week that is non-inferior in terms of local cancer control and is as safe as an international standard 15-fraction regimen after pri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53e395035946033bfb3c8db03e2d044a

ARB: Phase II window of opportunity study of short-term preoperative treatment with enzalutamide in ER-positive and triple-negative breast cancer

Autor: Peter Schmid, Duncan A Wheatley, Alastair Mark Thompson, Pankaj Roy, Nigel J Bundred, Anand David Purushotham, Stuart McINTOSH, Sherko Kummel, Nadia Harbeck, Ulrike Nitz, David Barnes, Shah-Jalal Sarker, Kelly Mousa, Javier Cortes

Publikováno v: Journal of Clinical Oncology. 34:TPS619-TPS619

TPS619Background: Theandrogen receptor (AR) is expressed in 60-80% of breast cancers (BC) across all molecular phenotypes, with a higher incidence in oestrogen receptor positive (ER+) BC compared to ER negative tumours. In ER+ disease, AR-expression

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e53919920ded69e819f0732d237c938b
https://doi.org/10.1200/jco.2016.34.15_suppl.tps619